• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Potentially fatal complications of systemic air embolism after computed tomography ‐guided transthoracic needle biopsy in lung cancer harboring epithelial growth factor receptor mutation: A case report
Systemic air embolism developed after CT ‐guided TTNB, leading to ST‐elevation, myocardial infarction and acute ischemic stroke. The patient recovered completely without sequelae and was diagnosed with adenocarcinoma harboring activatingEGFR mutation. Treatment with gefitinib showed a response. Air embolism is a rare, fatal complication of computed tomography (CT) ‐guided transthoracic needle biopsy (TTNB) of the lung. Here, we report a patient who developed an air embolism after CT‐guided TTNB, which led to ST‐elevation myocardial infarction and acute cerebral ischemia. The patient recovered completely without c...
Source: Thoracic Cancer - October 1, 2020 Category: Cancer & Oncology Authors: Hyung ‐Joo Oh, Won Gi Jeong, Yongwhan Lim, Sang‐Joon Koh, Sung Min Lee, Min‐Seok Kim, Bo‐Gun Koh, Tae‐Ok Kim, Yoo‐Duk Choi, In‐Jae Oh, Young‐Chul Kim, Cheol‐Kyu Park Tags: CASE REPORT Source Type: research

589PFluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: Preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
ConclusionsA high incidence of CV events, with no apparent correlation with CV comorbidities or risk factors, was observed. Prompt identification and treatment of CV events allowed most pts to complete the treatment with FP.Clinical trial identificationNCT02665312.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureM. Aglietta: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Merck; Advisory / Consultancy: Roche. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
Conclusions: Long-term abiraterone treatment was well tolerated in mCRPC patients with controlled cardiovascular comorbidities/risk factors, with no apparent worsening of cardiovascular conditions from baseline over an extended observation period.
Source: Therapeutic Advances in Medical Oncology - August 7, 2016 Category: Cancer & Oncology Authors: Verzoni, E., Grassi, P., Ratta, R., Niger, M., De Braud, F., Valdagni, R., Procopio, G. Tags: Original Research Source Type: research